NeoStem Inc Stock Nyse
Equities
NBS
US6406503051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jun. 13 | Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial | CI |
May. 20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 28.83M |
---|---|---|---|---|---|
Net income 2024 * | -25M | Net income 2025 * | -30M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-1.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
Latest transcript on NeoStem Inc
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- LSTA Stock
- NBS Stock